keyword
MENU ▼
Read by QxMD icon Read
search

Nab-paclitaxel

keyword
https://www.readbyqxmd.com/read/29770997/gemcitabine-nab-paclitaxel-for-pediatric-relapsed-refractory-sarcomas
#1
Jonathan L Metts, Adina L Alazraki, Dana Clark, Ernest K Amankwah, Karen J Wasilewski-Masker, Bradley A George, Thomas A Olson, Thomas Cash
BACKGROUND: Pediatric patients with relapsed/refractory sarcomas have poor outcomes and need novel therapies that provide disease control while maintaining an acceptable quality of life. The activity and toxicity of gemcitabine and nab-paclitaxel in combination has not been reported in pediatrics. PROCEDURE: We reviewed the records of fifteen relapsed/refractory patients and one treatment-naïve patient who received gemcitabine/nab-paclitaxel at our institution...
May 17, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29765563/targeted-therapies-in-the-management-of-locally-advanced-and-metastatic-pancreatic-cancer-a-systematic-review
#2
REVIEW
Anjali V Sheahan, Andrew V Biankin, Christopher R Parish, Levon M Khachigian
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach - combining chemotherapy with radiotherapy...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29764853/phase-i-study-of-cc-486-alone-and-in-combination-with-carboplatin-or-nab%C3%A2-paclitaxel-in-patients-with-relapsed-or-refractory-solid-tumors
#3
Daniel D Von Hoff, Drew W Rasco, Elisabeth I Heath, Pamela N Munster, Jan H M Schellens, Nicolas Isambert, Christophe Le Tourneau, Bert H O'Neil, Ron Hj Mathijssen, Jose A Lopez-Martin, William J Edenfield, Miguel Martín, Patricia M LoRusso, Gordon L Bray, Jorge DiMartino, Aaron Nguyen, Kejian Liu, Eric Laille, Johanna C Bendell
PURPOSE: This large two-part, three-arm phase I study examined the safety and tolerability of CC-486 (an oral formulation of azacitidine, a hypomethylating agent) alone or in combination with the cytotoxic agents, carboplatin or nab-paclitaxel, in patients with advanced unresectable solid tumors. PATIENTS AND METHODS: Part 1 (n=57) was a dose escalation of CC-486 alone (arm C) or with carboplatin (arm A) or nab-paclitaxel (arm B). The primary endpoint was safety, maximum tolerated dose, and recommended part 2 dose (RP2D) of CC-486...
May 15, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29764748/anticancer-drug-treatment-for-advanced-lung-cancer-with-interstitial-lung-disease
#4
REVIEW
Kohei Otsubo, Isamu Okamoto, Naoki Hamada, Yoichi Nakanishi
Interstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non-small cell lung cancer (NSCLC) with ILD because of the concern of acute exacerbation, and information on the effects of immune-checkpoint inhibitors is limited in these patients...
April 13, 2018: Respiratory Investigation
https://www.readbyqxmd.com/read/29761331/folfirinox-versus-gemcitabine-nab-paclitaxel-for-neoadjuvant-treatment-of-resectable-and-borderline-resectable-pancreatic-head-adenocarcinoma
#5
Mashaal Dhir, Mazen S Zenati, Ahmad Hamad, Aatur D Singhi, Nathan Bahary, Melissa E Hogg, Herbert J Zeh, Amer H Zureikat
BACKGROUND: Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA). This study aimed to compare neoadjuvant FOLFIRINOX and G-nP in the treatment of resectable (R) and borderline resectable (BR) head PDA. METHODS: A single-institution retrospective review of R and BR patients undergoing pancreaticoduodenectomy after NAT with FOLFIRINOX or G-nP was performed. Comparative analysis was performed using inverse-probability-weighted (IPW) estimators...
May 14, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29750040/a-phase-ib-study-of-ruxolitinib-gemcitabine-%C3%A2-nab-paclitaxel-in-patients-with-advanced-solid-tumors
#6
Todd M Bauer, Manish R Patel, Andres Forero-Torres, Thomas J George, Albert Assad, Yining Du, Herbert Hurwitz
Purpose: Aberrant activation of the Janus-associated kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is associated with increased malignant cell proliferation and survival. This Phase Ib study evaluated ruxolitinib, a potent JAK1/2 inhibitor, in combination with gemcitabine with or without nab-paclitaxel in patients with advanced solid tumors. Patients and methods: Patients received ruxolitinib + gemcitabine (regimen A) or ruxolitinib + gemcitabine + nab-paclitaxel (regimen B)...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29719799/nab-paclitaxel-plus-carboplatin-as-an-effective-and-safe-chemotherapy-regimen-for-pulmonary-carcinosarcoma-with-interstitial-lung-disease-a-case-report
#7
Hideyuki Niwa, Sakiko Otani, Norihiro Nakada, Jiichiro Sasaki, Hideo Saka, Noriyuki Masuda
Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin (CBDCA) achieves a favorable response rate in patients with non-small cell lung cancer (NSCLC). We administered nab-PTX + CBDCA to a 68-year-old man with postoperative recurrent carcinosarcoma with interstitial lung disease (ILD). A partial response was evident after four cycles of chemotherapy...
2018: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/29703690/quality-adjusted-survival-with-nab-paclitaxel-versus-standard-paclitaxel-in-metastatic-breast-cancer-a-q-twist-analysis
#8
Javier Cortes, José Pérez-García, Scott Whiting, Yin Wan, Caitlyn Solem, Ming-Hui Tai, Sandra Margunato-Debay, Amy Ko, Abderrahim Fandi, Marc Botteman
BACKGROUND: In this analysis we compared quality-adjusted survival outcomes between nab-paclitaxel (nab-P) and standard paclitaxel (Pac) using data from the nab-P phase III registration trial in metastatic breast cancer. PATIENTS AND METHODS: Quality-adjusted overall survival was estimated using the quality-adjusted time without symptoms or toxicity (Q-TWiST) approach. Overall survival was partitioned into time without progression/Grade ≥ 3 adverse events (AEs) toxicity (TWiST), time with Grade ≥ 3 AE toxicity (TOX), and time after relapse (REL)...
March 30, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29695765/phase-i-study-of-nab-paclitaxel-gemcitabine-and-bevacizumab-in-patients-with-advanced-cancers
#9
Shiraj Sen, Shumei Kato, Rishi Agarwal, Sarina Piha-Paul, Kenneth Hess, Daniel Karp, Filip Janku, Siqing Fu, Aung Naing, Shubham Pant, Gerald Falchook, Chad Tang, Xifeng Wu, Yuanqing Ye, Apostolia Tsimberidou, Vivek Subbiah, Razelle Kurzrock, Lauren Byers, Shannon Westin, JoAnn Lim, Stacie Bean, Allison Bass, Ly Nguyen, Funda Meric-Bernstam, David Hong
BACKGROUND: We performed a phase I modified 3 + 3 dose escalation study to evaluate the safety and activity of bevacizumab plus gemcitabine and nab-paclitaxel in patients with advanced solid tumours. METHODS: Patients were given fixed dose gemcitabine plus increasing doses of nab-paclitaxel and bevacizumab. Toxicity, response, and association with VEGF polymorphism was analysed. RESULTS: The study enrolled 110 patients who had undergone a median of 3 prior lines of therapy...
April 26, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29695574/biweekly-gemcitabine-nab-paclitaxel-as-first-line-treatment-for-advanced-pancreatic-cancer
#10
Stefania Kokkali, Elli-Sophia Tripodaki, Maria Drizou, Dimitra Stefanou, Elpida Magou, Dimosthenis Zylis, Matthaios Kapiris, Despoina Nasi, Chara Georganta, Alexandros Ardavanis
BACKGROUND/AIM: During recent years, a survival advantage was reported for first-line treatment of advanced pancreatic cancer with two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel, over gemcitabine monotherapy. Gemcitabine/nab-paclitaxel administration on days 1, 8 and 15 of a 4-week cycle is associated with some practical disadvantages. We adopted a biweekly regimen with the same dose density. PATIENTS AND METHODS: Patients with Eastern Cooperative Oncology Group performance status 0-2 diagnosed with advanced histologically or cytologically confirmed pancreatic cancer and no prior treatment were included in the study...
May 2018: In Vivo
https://www.readbyqxmd.com/read/29660567/summary-of-expression-of-sparc-protein-in-cutaneous-vascular-neoplasms-and-mimickers
#11
Shakuntala H Mauzo, Denái R Milton, Victor G Prieto, Carlos A Torres-Cabala, Wei-Lien Wang, Nitin Chakravarti, Priyadharsini Nagarajan, Michael T Tetzlaff, Jonathan L Curry, Doina Ivan, Robert E Brown, Phyu P Aung
BACKGROUND: Serum protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein, which regulates cell proliferation and facilitates intracellular transport of albumin bound particles including chemotherapeutic agents such as Nab-paclitaxel/ABI-007. Therefore the presence of SPARC may achieve higher intra-tumoral drug concentration with lower dosage and thus reduce systemic side-effects. Several trials of ABI-007, in melanoma, show promising clinical activity. DESIGN: Fifty-four cases of dermal based neoplasms were retrieved including 24 angiosarcomas (AS), 10 hemangiomas, 9 nodular melanomas, 4 Kaposi sarcomas (KS), 3 leiomyosarcomas (LMS), 3 atypical fibroxanthomas (AFX) and 1 spindle cell squamous cell carcinoma (SSCC)...
March 15, 2018: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/29658592/in-vitro-cytotoxic-effect-of-parp-inhibitor-alone-and-in-combination-with-nab%C3%A2-paclitaxel-on-triple%C3%A2-negative-and-luminal-a-breast-cancer-cells
#12
Mehmet Topçul, İdi L Çeti N, Suna Özbaş Turan, Melek Özlem Kolusayin Ozar
In the present study, the in vitro cytotoxic effect of poly(ADP‑ribose) polymerase (PARP) inhibitor alone and in combination with nab‑paclitaxel was evaluated on human triple‑negative breast cancer (TNBC) cell line MDA‑MB‑231 and human luminal A breast cancer cell line MCF‑7. For this purpose, cell index (CI) values obtained from xCELLigence Real‑Time Cell Analysis (RTCA) DP instrument, mitotic index (MI), labelling index (LI) and apoptotic index (AI) analysis among cell kinetic parameters were used...
April 12, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29651946/neoadjuvant-therapy-is-essential-for-resectable-pancreatic-cancer
#13
Jin-Zhi Xu, Wen-Quan Wang, Shi-Rong Zhang, Hua-Xiang Xu, Chun-Tao Wu, Zi-Hao Qi, He-Li Gao, Shuo Li, Quan-Xing Ni, Xian-Jun Yu, Liang Liu
BACKGROUND: Awareness of the benefits of neoadjuvant therapy is increasing, but its use as an initial therapeutic option for patients with resectable pancreatic cancer remains controversial, especially for those patients without high-risk prognostic features. Even for patients with high-risk features who are candidates to receive neoadjuvant therapy, no standard regimen exists. METHODS: In this review, we examined available data on neoadjuvant therapy in patients with resectable pancreatic cancer, including prospective studies, retrospective studies, and ongoing clinical trials, by searching PubMed/MEDLINE, ClinicalTrials...
April 12, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29651809/development-of-chemotherapy-and-significance-of-conversion-surgery-after-chemotherapy-in-unresectable-pancreatic-cancer
#14
REVIEW
Junji Furuse, Junji Shibahara, Masanori Sugiyama
While surgery currently remains the only potentially curative treatment available for pancreatic cancer, only 20% to 30% of patients have resectable disease at diagnosis. Recently, with the introduction of intensive chemotherapy regimens such as oxaliplatin, irinotecan, fluorouracil plus leucovorin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel, for the treatment of unresectable pancreatic cancer, the antitumor activity and overall survival in patients with pancreatic cancer have dramatically improved. These advances in intensive chemotherapy have led to the possibility of conversion of unresectable disease to resectable disease, and it has been reported that more than 20% of pancreatic cancer patients with unresectable locally advanced disease at diagnosis undergo successful conversion surgery after FOLFIRINOX therapy...
May 2018: Journal of Hepato-biliary-pancreatic Sciences
https://www.readbyqxmd.com/read/29650939/-a-case-of-successful-treatment-with-gemcitabine-plus-nab-paclitaxel-therapy-for-nonresected-pancreatic-body-cancer-stage-ivb
#15
Jun Kaneko, Ayako Kamiya, Kenta Kobayashi, Yasushi Takatsuno, Ito Kondoh, Kentaro Maejima, Jun Isogai, Kumi Hasegawa, Takeshi Endo, Shizuaki Maejima
A 61-year-old woman was introduced for consultation with a chief complaint of frequent vomiting. CT revealed a pancreatic body cancer approximately 40mm in size; an invading stenosis from the horizontal part of the duodenum to the jejunum, superior mesenteric artery, and portal vein, splenic vein obstruction, lymphadenopathy, and some ascitic fluid. We diagnosed a passage disorder due to the invasive stenosis from the horizontal part of the duodenum of the pancreatic body cancer to the jejunum, and subsequently performed a duodenum and jejunum bypass operation...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29644009/pomalidomide-enhanced-gemcitabine-and-nab-paclitaxel-on-pancreatic-cancer-both-in-vitro-and-in-vivo
#16
Nobuhiro Saito, Yoshihiro Shirai, Tadashi Uwagawa, Takashi Horiuchi, Hiroshi Sugano, Koichiro Haruki, Hiroaki Shiba, Toya Ohashi, Katsuhiko Yanaga
Background: Chemotherapy with gemcitabine and nab-paclitaxel (gemcitabine/nab-paclitaxel) is recommended for unresectable pancreatic cancer. However, the therapeutic efficacy is attenuated by the antitumor agent-induced activation of nuclear factor-κB (NF-κB). Thalidomide inhibits NF-κB activation, therefore, we hypothesized that pomalidomide, a third-generation IMiD, would also inhibit NF-κB activation and enhance the antitumor effects of gemcitabine/nab-paclitaxel. Methods: In vitro , we assessed NF-κB activity and apoptosis in response to pomalidomide alone, gemcitabine/nab-paclitaxel, or combination of pomalidomide and gemcitabine/nab-paclitaxel in human pancreatic cancer cell lines (PANC-1 and MIA PaCa-2)...
March 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29621664/chemotherapy-and-radiofrequency-induced-mild-hyperthermia-combined-treatment-of-orthotopic-pancreatic-ductal-adenocarcinoma-xenografts
#17
Martyna Krzykawska-Serda, Mahdi S Agha, Jason Chak-Shing Ho, Matthew J Ware, Justin J Law, Jared M Newton, Lam Nguyen, Steven A Curley, Stuart J Corr
Patients with pancreatic ductal adenocarcinomas (PDAC) have one of the poorest survival rates of all cancers. The main reason for this is related to the unique tumor stroma and poor vascularization of PDAC. As a consequence, chemotherapeutic drugs, such as nab-paclitaxel and gemcitabine, cannot efficiently penetrate into the tumor tissue. Non-invasive radiofrequency (RF) mild hyperthermia treatment was proposed as a synergistic therapy to enhance drug uptake into the tumor by increasing tumor vascular inflow and perfusion, thus, increasing the effect of chemotherapy...
April 2, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29616439/nab-paclitaxel-plus-gemcitabine-versus-folfirinox-as-the-first-line-chemotherapy-for-patients-with-metastatic-pancreatic-cancer-retrospective-analysis
#18
Jihoon Kang, Inhwan Hwang, Changhoon Yoo, Kyu-Pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Seung-Mo Hong, Sang Hyun Shin, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Song Cheol Kim, Baek-Yeol Ryoo
Purpose nab-paclitaxel plus gemcitabine (AG) and FOLFIRINOX have been established as standard first-line treatment in metastatic pancreatic cancer (mPC). We performed retrospective analysis comparing the efficacies of AG and FOLFIRINOX in daily practice setting. Materials and Methods We analyzed 308 patients who presented initially as mPC and received AG (n = 149) or FOLFIRINOX (n = 159) as first-line treatment between 2013 and 2016. Primary endpoints were progression-free survival (PFS) and overall survival (OS)...
April 3, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29605174/significant-association-between-low-baseline-neutrophil-to-lymphocyte-ratio-and-improved-progression-free-survival-of-patients-with-locally-advanced-or-metastatic-breast-cancer-treated-with-eribulin-but-not-with-nab-paclitaxel
#19
Yoshimasa Miyagawa, Kazuhiro Araki, Ayako Bun, Hiromi Ozawa, Yukie Fujimoto, Tomoko Higuchi, Arisa Nishimukai, Ayako Kira, Michiko Imamura, Yuichi Takatsuka, Yasuo Miyoshi
INTRODUCTION: Although eribulin and nab-paclitaxel are chemotherapy agents widely used for locally advanced or metastatic breast cancer (MBC), their predictive factors remain unknown. Because the absolute neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic factor for early-stage breast cancer, we investigated its usefulness in terms of the eribulin or nab-paclitaxel treatment efficacy for MBC. PATIENTS AND METHODS: A total of 85 patients with MBC treated with eribulin (n = 59) or nab-paclitaxel (n = 26) were recruited...
March 8, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29599680/the-first-case-of-drug-induced-pseudoscleroderma-and-eczema-craquel%C3%A3-related-to-nab-paclitaxel-pancreatic-adenocarcinoma-treatment
#20
Małgorzata Sokołowska-Wojdyło, Joanna Kłudkowska, Berenika Olszewska, Joanna Seredyńska, Wojciech Biernat, Izabela Błażewicz, Alicja Rustowska-Rogowska, Roman J Nowicki
No abstract text is available yet for this article.
February 2018: Postȩpy Dermatologii i Alergologii
keyword
keyword
18258
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"